On Saturday, December 9, at the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia, Scott Huntington, MD, MPH, will present his research team’s findings that the receipt of lymphoma care in the community-based setting is associated with guideline-discordant use of rituximab.
On Saturday, December 9, at the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia, Scott Huntington, MD, MPH, will present his research team’s findings that the receipt of lymphoma care in the community-based setting is associated with guideline-discordant use of rituximab.1
Maintenance rituximab monotherapy has been shown to improve progression-free survival in some lymphoma settings, but current guidelines support only 2 years of rituximab maintenance. Data from studies in other disease states suggest that financial incentives may influence the use of infused therapies in US patients, and Huntington and colleagues sought to determine whether community providers (who may have financial incentives to provide rituximab beyond guideline-based time periods) were more likely than hospital-employed providers to prescribe extended maintenance rituximab.
Using the SEER-Medicare database, the researchers identified older adults who were diagnosed with B-cell non-Hodgkin lymphoma between 2004 and 2011 and who had at least 1 claim for rituximab through 2013. Patients were included in the study if they had more than 7 months of claims for rituximab without a 200-day gap between claims.
The number of rituximab monotherapy claims and the duration of maintenance therapy were calculated for each patient until the receipt of chemotherapy, a 200-day gap in rituximab claims, or death, and the site of rituximab administration was classified as community or hospital-outpatient (as identified on Medicare claims). A logistic regression model was employed to assess the association between care setting and the prolonged use of rituximab monotherapy.
Overall, 2620 patients with 2 years of available follow-up after initiation of rituximab maintenance were identified; 75.1% received their rituximab therapy in a community setting. The median number of rituximab maintenance doses received was 9 (range, 1-103), and the median duration of maintenance was 14 months (range, 0-92), with 261 (10.0%) of patients receiving uninterrupted rituximab maintenance for more than 2 years.
Patients in the community setting were more likely to receive rituximab maintenance for longer than the guideline-recommended period; 11% of patients in the community setting versus 6.9% of patients in the hospital setting received more than 2 years of rituximab maintenance. Furthermore, treatment in a community setting was significantly associated with a patient’s receipt of more than 2 years of maintenance (adjusted odds ration [OR], 1.56; 95% CI, 1.10-2.20; P = .012) as well as with receipt of more than 12 doses of rituximab as monotherapy (adjusted OR = 2.01, 95% CI, 1.63-2.48; P < .001).
The authors concluded that receipt of lymphoma care in the community setting is associated with guideline-discordant use of rituximab, and that financial incentives for using anti-cancer therapies in this setting may contribute to the overuse of rituximab.
“Providers practicing in the physician-office setting are more likely to derive income directly from chemotherapy administration compared to hospital-employed physicians,” Huntington told The Center for Biosimilars® over email. “Prior research suggests physicians in community settings are more responsive to reimbursement changes in their choice of chemotherapy regimens compared to hospital-employed providers.”
While it is not known whether changes to reimbursement translate into treatment that is discordant with guidelines, Huntington said that “Financial incentives likely contribute to overutilization during rituximab maintenance, and future studies should consider treatment setting when evaluating cancer-therapy utilization. Our findings support ongoing efforts to minimize financial incentives tied to chemotherapy administration to better align payment with high quality care.”
Reference
1. Huntington S, Hoag J, Zhu W, Gross CP, Davidoff, AJ. Financial incentives and rituximab maintenance: association of treatment with prolonged maintenance in non-Hodgkin lymphoma patients treated in the United States. Presented at the American Society of Hematology 59th Annual Meeting and Exposition, December 9, 2017; Atlanta, Georgia. Abstract 2120. https://ash.confex.com/ash/2017/webprogram/Paper103349.html
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.